Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM and Crucell sign licensing agreement with GSK
Pursuant to the terms of the agreement, GSK will research a recombinant protein on the PER.C6 platform. Financial terms of the agreement were not disclosed. Crucell’s PER.C6 technology
Pursuant to the terms of the agreement, GSK will research a recombinant protein on the PER.C6 platform. Financial terms of the agreement were not disclosed. Crucell’s PER.C6 technology
The Peak surgery system, which received FDA clearance for use in general surgery in July 2008, includes the Peak PlasmaBlade family of disposable surgical cutting and coagulation devices.
According to SmartOps, enterprise inventory optimization (EIO) software enables customers to achieve both a rapid return on investment and a long-term competitive advantage by determining the best possible
In the six-week placebo-controlled study, Cognition Pharmaceuticals reported, the active group obtained significantly higher scores on secondary outcome measures of memory and learning, including the brief visuospatial memory
Located at 5202 Old Orchard Road in Skokie, Illinois, the new office will offer the latest in vein disease diagnosis and treatment. Ted King, medical director of Vein
Ligustrazine phosphate injection is used intravenously in hospital for treating ischemic cerebrovascular disease, such as insufficiency of blood-supply, cerebral thrombosis as well as cerebral embolism. Juan Han, chairman
The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Epliga for the adjunctive treatment of refractory partial onset seizures in patients with
The Phase IIb trial is designed to assess the effect of Kai-9803 on reducing myocardial injury in patients with ST segment elevation myocardial infarction (STEMI) who are undergoing
This agreement is a result of the previously announced intention to close Devgen’s pharma division. This closure will lead to the employment of the 19 employees, active in
As per the terms of the settlement, Lupin will be licensed under the relevant desloratadine patents, and free to commercially launch its generic desloratadine product, on July 1,